These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 6814139)

  • 21. Ultrasonographic and endocrine evaluation of ovarian function among Norplant implants users with regular menses.
    Alvarez F; Brache V; Faundes A; Tejada AS; Thevenin F
    Contraception; 1996 Nov; 54(5):275-9. PubMed ID: 8934060
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of vaginal administration of low-dose oral contraceptive tablets on human ovulation.
    Souka AR; el Sokkary H; Kamel M; Hassan M
    Contraception; 1986 Apr; 33(4):365-71. PubMed ID: 3731776
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The interaction between sex hormone binding globulin and levonorgestrel released from vaginal rings in women.
    Cekan SZ; Jia M; Landgren BM; Diczfalusy E
    Contraception; 1985 Apr; 31(4):431-9. PubMed ID: 3924477
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of levonorgestrel administered in large doses at different stages of the cycle on ovarian function and endometrial morphology.
    Landgren BM; Johannisson E; Aedo AR; Kumar A; Shi YE
    Contraception; 1989 Mar; 39(3):275-89. PubMed ID: 2496951
    [TBL] [Abstract][Full Text] [Related]  

  • 25. d-Norgestrel concentrations in maternal plasma, milk, and child plasma during administration of oral contraceptives to nursing women.
    Nilsson S; Nygren KG; Johansson ED
    Am J Obstet Gynecol; 1977 Sep; 129(2):178-84. PubMed ID: 900181
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Suppression of ovarian function by Microgynon 30 in day 1 and day 5 "starters".
    Taylor DR; Anthony FW; Dennis KJ
    Contraception; 1986 May; 33(5):463-71. PubMed ID: 3757512
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ovulation detection following removal of levonorgestrel subdermal contraceptive implants.
    Ismail AA; Anwar MY; Youssef SM; Toppozada M
    Contraception; 1987 Mar; 35(3):207-14. PubMed ID: 3111783
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Levonorgestrel plasma levels during continuous administration with different models of subdermal implants.
    Alvarez F; Brache V; Faundes A; Johansson ED; Odlind V; Nash H
    Contraception; 1983 Feb; 27(2):123-30. PubMed ID: 6406138
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of folliculogenesis and ovulation by the antiprogesterone RU 486.
    Luukkainen T; Heikinheimo O; Haukkamaa M; Lähteenmäki P
    Fertil Steril; 1988 Jun; 49(6):961-3. PubMed ID: 3371492
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A two-year clinical study of the effects of two triphasic oral contraceptives on plasma lipids.
    Kakis G; Powell M; Marshall A; Woutersz TB; Steiner G
    Int J Fertil Menopausal Stud; 1994; 39(5):283-91. PubMed ID: 7820162
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Studies on ovarian function in users of the progestagen only contraceptive pill.
    Tayob Y; Guillebaud J; Adams J; Jacobs HS
    J Obstet Gynaecol (Lahore); 1986 Apr; 6 Suppl 2():S91-5. PubMed ID: 12315277
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term reversible contraception with levonorgestrel-releasing Silastic rods.
    Roy S; Mishell DR; Robertson DN; Krauss RM; Lacarra M; Duda MJ
    Am J Obstet Gynecol; 1984 Apr; 148(7):1006-13. PubMed ID: 6424474
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Suppression of ovarian function with the transdermally given synthetic progestin ST 1435.
    Laurikka-Routti M; Haukkamaa M; Lähteenmäki P
    Fertil Steril; 1992 Oct; 58(4):680-4. PubMed ID: 1426309
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ovarian function during treatment with high ratio levonorgestrel/ethinyl estradiol as oral contraceptives.
    Johansson ED; Elamsson K; Elmestedt U
    Gynecol Obstet Invest; 1982; 14(2):97-105. PubMed ID: 6811379
    [No Abstract]   [Full Text] [Related]  

  • 35. Mode of action of dl-norgestrel and ethinylestradiol combination in postcoital contraception. II. Effect of postovulatory administration on ovarian function and endometrium.
    Ling WY; Wrixon W; Zayid I; Acorn T; Popat R; Wilson E
    Fertil Steril; 1983 Mar; 39(3):292-7. PubMed ID: 6402387
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ovarian function in amenorrheic and menstruating users of a levonorgestrel-releasing intrauterine device.
    Nilsson CG; Lähteenmäki PL; Luukkainen T
    Fertil Steril; 1984 Jan; 41(1):52-5. PubMed ID: 6420203
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Factors affecting pituitary gonadotropin function in users of oral contraceptive steroids.
    Scott JA; Brenner PF; Kletzky OA; Mishell DR
    Am J Obstet Gynecol; 1978 Apr; 130(7):817-21. PubMed ID: 345817
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ovarian function during use of a levonorgestrel-releasing IUD.
    Barbosa I; Bakos O; Olsson SE; Odlind V; Johansson ED
    Contraception; 1990 Jul; 42(1):51-66. PubMed ID: 2117516
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum steroid binding protein concentrations, distribution of progestogens, and bioavailability of testosterone during treatment with contraceptives containing desogestrel or levonorgestrel.
    Hammond GL; Langley MS; Robinson PA; Nummi S; Lund L
    Fertil Steril; 1984 Jul; 42(1):44-51. PubMed ID: 6233179
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Three-year experience with NORPLANT subdermal contraception.
    Sivin I; Sanchez FA; Diaz S; Holma P; Coutinho E; McDonald O; Robertson DN; Stern J
    Fertil Steril; 1983 Jun; 39(6):799-808. PubMed ID: 6406273
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.